GSE107423
Next generation sequencing facilitates quantitative analysis of murine high-grade glibablastoma Transcriptomes after VEGF-A blockade In Vivo.
The goals of this study are to compare immunogenic profiling of tumor tissue from GL261 burden mice were treated with different dose VEGF-A antibody from Day10 after tumor implantation to the endpoint. The treatment doses are 0ug, 50ug, 100ug and 200ug. Overall design: mRNA profiles of  healthy brain tissue  and tumors tissure  harvested from GL261 burden mice after VEGF-A blockade treatment were generated by RNA sequencing. There are 3 individual samples in each treatmen group.